Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Non-Current Liabilities (2016 - 2026)

Akebia Therapeutics has reported Total Non-Current Liabilities over the past 11 years, most recently at $342.1 million for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 29.26% to $342.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $342.1 million through Dec 2025, up 29.26% year-over-year, with the annual reading at $342.1 million for FY2025, 29.26% up from the prior year.
  • Total Non-Current Liabilities was $342.1 million for Q4 2025 at Akebia Therapeutics, up from $317.6 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $453.5 million in Q4 2021 and troughed at $246.0 million in Q1 2024.
  • The 5-year median for Total Non-Current Liabilities is $309.9 million (2025), against an average of $322.7 million.
  • Year-over-year, Total Non-Current Liabilities crashed 35.04% in 2023 and then grew 29.26% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $453.5 million in 2021, then dropped by 22.81% to $350.1 million in 2022, then dropped by 22.22% to $272.3 million in 2023, then dropped by 2.79% to $264.7 million in 2024, then increased by 29.26% to $342.1 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Total Non-Current Liabilities are $342.1 million (Q4 2025), $317.6 million (Q3 2025), and $302.2 million (Q2 2025).